Geode Capital Management, LLC Tyme Technologies, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	BUY	$0.23 - $0.35 $8,472 - $12,892	36,836 Added 4.82%	800,667 $224,000
Q4 2021 Feb 11, 2022	SELL	$0.6 - $1.04 $7 - $12	-12 Reduced -0.0%	763,831 $460,000
Q3 2021 Nov 12, 2021	SELL	$0.99 - $1.38 $64,453 - $89,844	-65,105 Reduced 7.85%	763,843 $786,000
Q2 2021 Aug 13, 2021	SELL	$1.14 - $1.87 $519,477 - $852,125	-455,682 Reduced 35.47%	828,948 $1.04 Million
Q1 2021 May 12, 2021	BUY	$1.34 - $3.53 $528,230 - $1.39 Million	394,202 Added 44.27%	1,284,630 $2.29 Million
Q4 2020 Feb 12, 2021	BUY	$0.87 - $1.26 $24,820 - $35,946	28,529 Added 3.31%	890,428 $1.09 Million
Q3 2020 Nov 13, 2020	BUY	$0.93 - $1.35 $46,095 - $66,912	49,565 Added 6.1%	861,899 $844,000
Q2 2020 Aug 13, 2020	BUY	$0.97 - $1.7 $29,908 - $52,417	30,834 Added 3.95%	812,334 $1.08 Million
Q1 2020 May 14, 2020	BUY	$0.9 - $1.95 $34,479 - $74,704	38,310 Added 5.15%	781,500 $859,000
Q4 2019 Feb 13, 2020	BUY	$1.0 - $1.49 $18,481 - $27,536	18,481 Added 2.55%	743,190 $1.04 Million
Q3 2019 Nov 12, 2019	BUY	$0.97 - $1.77 $75,411 - $137,606	77,744 Added 12.02%	724,709 $862,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $110,492 - $217,531	-115,096 Reduced 15.1%	646,965 $789,000
Q1 2019 May 14, 2019	BUY	$1.76 - $3.73 $127,510 - $270,234	72,449 Added 10.51%	762,061 $1.34 Million
Q4 2018 Feb 13, 2019	BUY	$2.01 - $4.21 $1 Million - $2.1 Million	499,627 Added 262.98%	689,612 $2.54 Million
Q3 2018 Nov 13, 2018	BUY	$2.18 - $3.44 $177,619 - $280,280	81,477 Added 75.09%	189,985 $528,000
Q2 2018 Aug 14, 2018	BUY	$2.05 - $4.09 $222,441 - $443,797	108,508 New	108,508 $342,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.